Delphia (USA)’s Kalaris Therapeutics KLRS Stock Holding History

Delphia (USA)’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-491	Closed	-$44K	–	436
2022 Q2	$44K	Buy	+491	New	+$51.5K	0.03%	373

Other funds holding KLRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Delphia (USA)'s KLRS Position: Q3 2022 in Review

Delphia (USA) sold out of Kalaris Therapeutics (KLRS) in Q3 2022, closing a stake of 491 shares — an estimated $44K sold.

Delphia (USA) first reported a position in KLRS in Q2 2022 and held it in 1 quarter. The position peaked at $44K in Q2 2022. 85 funds tracked by Wall St. Rank hold KLRS as of Q3 2022.

Delphia (USA) reported no remaining Kalaris Therapeutics position as of Q3 2022 after selling out during the quarter.
Delphia (USA) sold 491 Kalaris Therapeutics shares in Q3 2022, an estimated $44K.
Delphia (USA) first reported a position in Kalaris Therapeutics in Q2 2022 and held it in 1 quarter.
Delphia (USA)'s Kalaris Therapeutics position peaked at $44K in Q2 2022.
85 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2022.

Based on Delphia (USA)'s 13F filing for Q3 2022, filed 14 Nov 2022.